Pazopanib
Active ingredient: Pazopanib
In short: Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma (RCC). Pazopanib tablets are indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.
What is Pazopanib used for?
Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma (RCC).
Pazopanib tablets are indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.
Limitations of Use: The efficacy of pazopanib tablets for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated.
⚠ Boxed warning (FDA's strongest warning)
WARNING: HEPATOTOXICITY
Severe and fatal hepatotoxicity has been observed in clinical trials. Monitor hepatic function and interrupt, reduce, or discontinue dosing as recommended
.
Pazopanib dosage
The recommended dosage of pazopanib tablets is 800 mg (four 200 mg tablets) orally once daily without food (at least 1 hour before or 2 hours after a meal) until disease progression or unacceptable toxicity
.
The dosage should be modified for hepatic impairment and in patients taking certain concomitant drugs
.
Swallow tablets whole. Do not crush tablets due to the potential for increased rate of absorption, which may affect systemic exposure
.
If a dose is missed, it should not be taken if it is <12 hours until the next dose.
Table 1 summarizes the recommended dose reductions.
Table 1. Recommended Dose Reductions of Pazopanib tablets for Adverse Reactions
Dose Reduction | For Renal Cell Carcinoma | For Soft Tissue Sarcoma
First | 400 mg orally once daily | 600 mg orally once daily
Second | 200 mg orally once daily | 400 mg orally once daily
Permanently discontinue pazopanib tablets in patients unable to tolerate the second dose reduction.
Table 2 summarizes the recommended dosage modifications for adverse reactions.
Table 2. Recommended Dosage Modifications of Pazopanib Tablets for Adverse Reactions
Adverse Reaction | Severity
a | Dosage Modification
Hepatic Toxicity
| Isolated ALT elevations between 3 x ULN and 8 x ULN | Continue and monitor liver function weekly until ALT returns to Grade 1 or baseline.
Isolated ALT elevations of > 8 x ULN | Withhold until improvement to Grade 1 or baseline. If the potential benefit for resuming treatment with pazopanib tablets is considered to outweigh the risk for hepatotoxicity, then resume at a reduced dose of no more than 400 mg once daily and measure serum liver tests weekly for 8 weeks. Permanently discontinue if ALT elevations > 3 x ULN recur despite dose reduction(s).
ALT elevations > 3 x ULN occur concurrently with bilirubin elevations > 2 x ULN | Permanently discontinue and continue to monitor until resolution. Patients with only a mild, indirect (unconjugated) hyperbilirubinemia, known as Gilbert's syndrome, and ALT elevations > 3 x ULN should be managed per the recommendations outlined for isolated ALT elevations.
Left Ventricular Systolic Dysfunction
| Symptomatic or Grade 3 | Withhold until improvement to Grade < 3. Resume treatment based on medical judgement.
Grade 4 | Permanently discontinue.
Hemorrhagic Events
| Grade 2 | Withhold until improvement to Grade ≤ 1. Resume at reduced dose . Permanently discontinue if Grade 2 recurs after dose interruption and reduction.
Grade 3 or 4 | Permanently discontinue.
Arterial Thromboembolic Events
| Any grade | Permanently discontinue.
Venous Thromboembolic Events
| Grade 3 | Withhold pazopanib tablets and resume at same dose if managed with appropriate therapy for at least one week.
Grade 4 | Permanently discontinue. …
How to take Pazopanib — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Hepatic Toxicity:Inform patients that periodic laboratory testing will be performed. Advise patients to report signs and symptoms of liver dysfunction to their healthcare provider right away
.
QT Prolongation and Torsades de Pointes:Inform patients that ECG monitoring may be performed. Advise patients to inform their physicians of concomitant medications
.
Interstitial Lung Disease/Pneumonitis: Advise patients to report pulmonary signs or symptoms indicative of interstitial lung disease (ILD) or pneumonitis
.
Cardiac Dysfunction:Advise patients to report hypertension or signs and symptoms of congestive heart failure
.
Hemorrhagic Events: Advise patients to report unusual bleeding
.
Arterial Thromboembolic Events:Advise patients to report signs or symptoms of an arterial thrombosis
.
Pneumothorax and Venous Thromboembolic Events:Advise patients to report new onset of dyspnea, chest pain, or localized limb edema
. …
Warnings & precautions
Do not take this medicine if: None.
Hepatotoxicity, manifested as increases in ALT, aspartate aminotransferase (AST) and bilirubin, occurred in patients who received pazopanib tablets. This hepatotoxicity can be severe and fatal. Patients older than 65 years are at greater risk for hepatotoxicity
.
Transaminase elevations occur early in the course of treatment; 92% of all transaminase elevations of any grade occurred in the first 18 weeks.
In the randomized RCC trial (VEG105192), ALT > 3 x ULN occurred in 18% and ALT > 10 x ULN occurred in 4% of the 290 patients who received pazopanib tablets. Concurrent elevation in ALT > 3 x ULN and bilirubin > 2 x ULN in the absence of significant alkaline phosphatase > 3 x ULN occurred in 2%. In the monotherapy trials, 2 patients died with disease progression and hepatic failure.
In the randomized STS trial (VEG110727), ALT > 3 x ULN occurred in 18% and ALT > 8 x ULN occurred in 5% of the 240 patients who received pazopanib tablets. Concurrent elevation in ALT > 3 x ULN and bilirubin > 2 x ULN in the absence of significant alkaline phosphatase > 3 x ULN occurred in 2%. One patient died of hepatic failure.
Monitor liver tests at baseline; at Weeks 3, 5, 7, and 9; at Month 3 and Month 4; and then periodically as clinically indicated. Increase to weekly monitoring for patients with elevated ALT until ALT returns to Grade 1 or baseline. Withhold pazopanib tablets and resume at reduced dose with continued weekly monitoring for 8 weeks, or permanently discontinue with weekly monitoring until resolution based on severity of hepatotoxicity
.
Gilbert's Syndrome
Pazopanib tablets is a uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1) inhibitor. Mild, indirect (unconjugated) hyperbilirubinemia may occur in patients with Gilbert's syndrome
. …
Pazopanib side effects
The following clinically significant adverse reactions are elsewhere in the labeling:
Hepatic Toxicity
QT Prolongation and Torsades de Pointes
Cardiac Dysfunction
Hemorrhagic Events
Arterial Thromboembolic Events
Venous Thromboembolic Events
Thrombotic Microangiopathy (TMA)
Gastrointestinal Perforation and Fistula
Interstitial Lung Disease (ILD)/Pneumonitis
Posterior Reversible Encephalopathy Syndrome (PRES)
Hypertension
Hypothyroidism
Proteinuria
Tumor Lysis Syndrome
Infection
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The data described in the WARNINGS AND PRECAUTIONS section reflect exposure of 977 patients who received pazopanib tablets as a single agent, including 586 pazopanib-treated patients with RCC. With a median duration of treatment of 7.4 months (range, 0.1 to 27.6) in these 977 patients, the most common adverse reactions (≥ 20%) in these 586 patients were diarrhea, hypertension, hair color change, nausea, fatigue, anorexia, and vomiting.
The data described in the WARNINGS AND PRECAUTIONS also reflects exposure of 382 patients with advanced soft tissue sarcoma who received pazopanib tablets as a single agent, with a median duration of treatment of 3.6 months (range, 0 to 53). …
Drug interactions
Strong CYP3A4 Inhibitors
Coadministration of pazopanib with strong inhibitors of CYP3A4 increases pazopanib concentrations . Avoid coadministration of pazopanib tablets with strong CYP3A4 inhibitors and consider an alternate concomitant medication with no or minimal enzyme inhibition potential. If coadministration of a strong CYP3A4 inhibitor cannot be avoided, reduce the dose of pazopanib tablets
.
Strong CYP3A4 Inducers
Coadministration of strong CYP3A4 inducers may decrease plasma pazopanib concentrations. Consider an alternate concomitant medication with no or minimal enzyme induction potential. Pazopanib tablets are not recommended if chronic use of strong CYP3A4 inducers cannot be avoided
.
Transporters
Coadministration of strong inhibitors of P-gp or BCRP may increase pazopanib concentrations. Avoid concomitant use of pazopanib tablets with strong inhibitors of P-gp or BCRP. Consider selection of alternative concomitant medicinal products with no or minimal potential to inhibit P-gp or BCRP.
CYP Substrates
Coadministration of pazopanib tablets with agents with narrow therapeutic windows that are metabolized by CYP3A4, CYP2D6, or CYP2C8 may result in inhibition of the metabolism of these products and create the potential for serious adverse reactions. …
About this medicine
Pazopanib is a kinase inhibitor. Pazopanib is presented as the hydrochloride salt, with the chemical name 5-[[4-[(2,3-Dimethyl-2
H-indazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide monohydrochloride. It has the molecular formula C
21H
23N
7O
2S·HCl and a molecular weight of 473.98 g/mol. Pazopanib hydrochloride has the following chemical structure:
Pazopanib hydrochloride is a white to slightly yellow solid. It is very slightly soluble in aqueous solutions, being practically insoluble above pH 4.
Pazopanib tablets are for oral use. Each 200-mg tablet of pazopanib tablets contains 200 mg of pazopanib equivalent to 216.7 mg of pazopanib hydrochloride. The inactive ingredients of pazopanib tablets are:
Tablet Core:magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate.
Coating:Gray film-coat: hydroxypropyl cellulose, hydroxypropyl methylcellulose, iron oxide black, polyethylene glycol 8000, and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 115eb5bb-1403-fb3d-e063-6394a90ad320. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate